Skip to main content

Table 2 Clinical and laboratory effects of MARS therapy

From: Equipment review: The molecular adsorbents recirculating system (MARS®)

   Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Parameter Normal range Before After Before After Before After Before After Before After
Noradrenaline, μg kg-1 min-1   0.22 0.02 0.06 0.16 0 0 0.22 0.10 0.32 0.06
Creatinine 60–110 μM 307 142 132 239 171 234 241 144 164 107
Urea 2.9–7.1 mM 21 13 16 22 1 6 11 29 15 17
Ammonia 15–50 μM 67 47         
HE grade   4 3      3 1 3 2
Bilirubin <25 μM 161 210 654 528 260 182 484 137 510 326
Bile acids 0–6 μM 75 75      27 16 202 67
AA/β-OH-But   4.2 6.8      1.3 8 4 4.5
PDR ICG >16% min-1 4.4 5.5 4.3 5.2 4.3 5.4 5.6 5.2   
Duration of treatment, h   24, 16 15, 13 5, 6 12, 16, 20 6, 6, 6
Outcome   ICU D/C, died in ward Died in ICU ICU D/C, died in ward D/C home Died in ICU
  1. AA/β-OH-But, ratio of arterial acetoacetate to β-hydroxybutyrate (ketone body); D/C, discharged; HE, hepatic encephalopathy; ICU, intensive care unit; PDR ICG, plasma disappearance rate of indocyanine green (measured after an intravenous dose of 0.5 mg kg-1 body weight with a non-invasive transcutaneous probe [Pulsion Medical System AG, Munich]).